<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: During ovulation induction (OI), ovarian stimulation is accomplished by hormonal manipulation, which includes administration of gonadotropins, gonadotropin-releasing hormone <z:chebi fb="4" ids="48705">agonists</z:chebi>, follicle-stimulating hormone, and luteinizing hormone </plain></SENT>
<SENT sid="1" pm="."><plain>In in vitro fertilization (IVF), <z:chebi fb="28" ids="17026">progesterone</z:chebi> is often added </plain></SENT>
<SENT sid="2" pm="."><plain>Because of the possibility of hormone-associated flare or <z:mp ids='MP_0005048'>thrombosis</z:mp>, patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (primary APS) undergoing OI/IVF are potentially at increased risk </plain></SENT>
<SENT sid="3" pm="."><plain>The present study was conducted in order to assess this risk </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Nineteen women who underwent 68 cycles of OI/IVF were studied by interview and retrospective chart review </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Four OI/IVF cycles (25%) in SLE patients resulted in increased <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> activity and 2 (13%) in <z:e sem="disease" ids="C0085083" disease_type="Disease or Syndrome" abbrv="OHSS">ovarian hyperstimulation syndrome</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>One patient with primary APS who was given <z:chebi fb="5" ids="28304">heparin</z:chebi> during multiple cycles developed <z:hpo ids='HP_0000938'>osteopenia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>No <z:mp ids='MP_0005048'>thrombosis</z:mp> occurred </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0032962" disease_type="Disease or Syndrome" abbrv="">Pregnancy complications</z:e> included <z:e sem="disease" ids="C0040524,C0032914" disease_type="Disease or Syndrome" abbrv="">toxemia</z:e>, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> flare, <z:hpo ids='HP_0002239'>gastrointestinal hemorrhage</z:hpo> due to <z:e sem="disease" ids="C0024633" disease_type="Disease or Syndrome" abbrv="">Mallory-Weiss tear</z:e>, polygestation, and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C0852263" disease_type="Disease or Syndrome" abbrv="">Postpartum complications</z:e> included <z:hpo ids='HP_0000123'>nephritis</z:hpo> flare, <z:e sem="disease" ids="C0040213" disease_type="Disease or Syndrome" abbrv="">costochondritis</z:e>, and suicidal <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> flares occurred at expected rates </plain></SENT>
<SENT sid="11" pm="."><plain>Five of 16 cycles (31%) in 7 SLE patients, 5 of 48 cycles (10%) in 10 primary APS patients, and 0 of 5 cycles in 2 women with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> (without SLE or primary APS) resulted in liveborn children, including multiple gestations (3 twin sets with 4 surviving infants and 2 triplet sets with 3 surviving infants) </plain></SENT>
<SENT sid="12" pm="."><plain>Seven of 14 living children (50%) were premature, 3 had <z:e sem="disease" ids="C0409979" disease_type="Disease or Syndrome" abbrv="">neonatal lupus</z:e>, and 1 had <z:hpo ids='HP_0001642'>pulmonic stenosis</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Five surviving infants (38%) had complications unrelated to <z:e sem="disease" ids="C0728731" disease_type="Disease or Syndrome" abbrv="">prematurity</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Although OI/IVF can be successful in SLE and primary APS patients, rates of fetal and maternal complications are high </plain></SENT>
</text></document>